KEAP1 and diabetes mellitus: After administration of PAOS or glibenclamide, the level of Keap1 was significantly downregulated (p = 0.0024, p = 0.0005, p = 0.0029), and the expressions of Nrf2 and HO-1 were upregulated (p = 0.0188, p = 0.0057, p = 0.007; p = 0.0007, p = 0.0104, p = 0.0012) in DM.